GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lytix Biopharma AS (STU:6BG) » Definitions » Institutional Ownership

Lytix Biopharma AS (STU:6BG) Institutional Ownership : 3.66% (As of Apr. 28, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Lytix Biopharma AS Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Lytix Biopharma AS's institutional ownership is 3.66%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Lytix Biopharma AS's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Lytix Biopharma AS's Float Percentage Of Total Shares Outstanding is 0.00%.


Lytix Biopharma AS Institutional Ownership Historical Data

The historical data trend for Lytix Biopharma AS's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lytix Biopharma AS Institutional Ownership Chart

Lytix Biopharma AS Historical Data

The historical data trend for Lytix Biopharma AS can be seen below:

2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 3.67 3.66 3.66 3.66

Lytix Biopharma AS Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Lytix Biopharma AS Business Description

Traded in Other Exchanges
Address
Sandakerveien 138, Oslo, NOR, 0484
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. Its products, LTX-401, and LTX-315 are in the pipeline.

Lytix Biopharma AS Headlines

No Headlines